DIAGNOSTICOS DA AMÉRICA S.A. Financials Diagnosticos da América S.A.
Equities
DASA3
BRDASAACNOR1
Healthcare Facilities & Services
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.62 BRL | +13.24% |
|
+21.69% | -52.18% |
| Jun. 10 | Brazil's Dasa, Amil in advanced talks to combine hospital businesses | RE |
| May. 16 | Transcript : Diagnósticos da América S.A., Q1 2024 Earnings Call, May 16, 2024 |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 34,851 | 18,485 | 7,686 | 7,186 | 3,049 | - | - |
| Enterprise Value (EV) 1 | 34,851 | 26,409 | 7,686 | 16,167 | 14,945 | 13,400 | 13,147 |
| P/E ratio | - | -90.8 x | -19.8 x | -6.16 x | 13.8 x | 4.8 x | - |
| Yield | - | 0.89% | - | - | 0.12% | 3.59% | - |
| Capitalization / Revenue | 4.95 x | 1.77 x | 0.59 x | 0.46 x | 0.19 x | 0.18 x | 0.17 x |
| EV / Revenue | 4.95 x | 2.53 x | 0.59 x | 1.04 x | 0.95 x | 0.81 x | 0.75 x |
| EV / EBITDA | - | 20.6 x | 3.54 x | 6.91 x | 5.31 x | 4.3 x | 3.84 x |
| EV / FCF | - | -7.23 x | - | -9.11 x | 33.4 x | 14.1 x | 10.7 x |
| FCF Yield | - | -13.8% | - | -11% | 2.99% | 7.08% | 9.31% |
| Price to Book | - | 2.51 x | - | 0.99 x | 0.4 x | 0.39 x | - |
| Nbr of stocks (in thousands) | 480,705 | 547,872 | 559,827 | 746,960 | 747,191 | - | - |
| Reference price 2 | 72.50 | 33.74 | 13.73 | 9.620 | 4.080 | 4.080 | 4.080 |
| Announcement Date | 3/7/21 | 3/28/22 | 3/28/23 | 3/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 7,039 | 10,419 | 13,129 | 15,557 | 15,731 | 16,628 | 17,519 |
| EBITDA 1 | - | 1,282 | 2,168 | 2,339 | 2,815 | 3,117 | 3,427 |
| EBIT 1 | - | 351.7 | 1,102 | 913.3 | 1,645 | 1,900 | 2,091 |
| Operating Margin | - | 3.38% | 8.39% | 5.87% | 10.46% | 11.43% | 11.93% |
| Earnings before Tax (EBT) 1 | - | -374.2 | -578.8 | -996 | 254 | 582.5 | 332 |
| Net income 1 | -150.8 | -226.6 | -386.9 | -1,130 | 71.65 | 475.3 | 478.2 |
| Net margin | -2.14% | -2.17% | -2.95% | -7.26% | 0.46% | 2.86% | 2.73% |
| EPS 2 | - | -0.3715 | -0.6932 | -1.561 | 0.2950 | 0.8500 | - |
| Free Cash Flow 1 | - | -3,654 | - | -1,775 | 447 | 949 | 1,224 |
| FCF margin | - | -35.07% | - | -11.41% | 2.84% | 5.71% | 6.99% |
| FCF Conversion (EBITDA) | - | - | - | - | 15.88% | 30.44% | 35.72% |
| FCF Conversion (Net income) | - | - | - | - | 623.86% | 199.65% | 255.93% |
| Dividend per Share 2 | - | 0.3012 | - | - | 0.005000 | 0.1467 | - |
| Announcement Date | 3/7/21 | 3/28/22 | 3/28/23 | 3/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,673 | 3,136 | 3,288 | 3,425 | 3,279 | 3,534 | 3,631 | 3,769 | 3,777 | 3,728 | 3,903 | 4,046 |
| EBITDA | 222.9 | 560.5 | 512.3 | 607.3 | 457.6 | 615.7 | 526.1 | 660.8 | 438 | 638.7 | - | - |
| EBIT 1 | -39.21 | 288.4 | 227.3 | 307.9 | 208 | 306 | 215.4 | 331 | 60.98 | 303.2 | 404.4 | 511.7 |
| Operating Margin | -1.47% | 9.2% | 6.91% | 8.99% | 6.34% | 8.66% | 5.93% | 8.78% | 1.61% | 8.13% | 10.36% | 12.65% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | -167.1 | 37.11 | -120.1 | -89.36 | -214.6 | -166 | -282.1 | -180.5 | -495 | -176 | - | - |
| Net margin | -6.25% | 1.18% | -3.65% | -2.61% | -6.54% | -4.7% | -7.77% | -4.79% | -13.11% | -4.72% | - | - |
| EPS 2 | -0.2630 | 0.0636 | -0.2145 | -0.1592 | -0.3853 | -0.3019 | -0.3803 | - | - | -0.2355 | 0.0200 | 0.1100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/12/22 | 8/11/22 | 11/14/22 | 3/28/23 | 5/12/23 | 8/10/23 | 11/9/23 | 3/28/24 | 5/15/24 | - | - |
1BRL in Million2BRL
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 7,924 | - | 8,981 | 11,896 | 10,352 | 10,099 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 6.183 x | - | 3.84 x | 4.226 x | 3.32 x | 2.947 x |
| Free Cash Flow 1 | - | -3,654 | - | -1,775 | 447 | 949 | 1,224 |
| ROE (net income / shareholders' equity) | - | -4.09% | - | -16.2% | 4.7% | 6.43% | 8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 13.50 | - | 9.740 | 10.30 | 10.50 | - |
| Cash Flow per Share | - | 2.320 | - | -1.290 | - | - | - |
| Capex 1 | - | 4,952 | - | 727 | 841 | 774 | 860 |
| Capex / Sales | - | 47.53% | - | 4.67% | 5.35% | 4.65% | 4.91% |
| Announcement Date | 3/7/21 | 3/28/22 | 3/28/23 | 3/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.08
BRL
Average target price
9.625
BRL
Spread / Average Target
+135.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -57.59% | 543M | |
| +26.08% | 89.38B | |
| -23.66% | 75.67B | |
| +6.34% | 28.83B | |
| +5.38% | 18.25B | |
| -13.80% | 16.51B | |
| +2.60% | 15.72B | |
| +78.26% | 13.71B | |
| +82.29% | 13.46B | |
| +23.94% | 12.64B |
- Stock Market
- Equities
- DASA3 Stock
- Financials Diagnosticos da América S.A.
